MM

Mark McDade

Qiming Venture Partners USA

Seattle, Washington

VC
Investor
Founder

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Oncology
Pharmaceutical Industry
Cross-functional Team Leadership
R&D funding
Technology Transfer
Clinical Trials
Lifesciences
Biotechnology
Regulatory Affairs
People Development
Corporate Development
Clinical Development
Start-ups
Technical Operations
Venture Capital
Biopharmaceuticals
Strategy
FDA
Commercialization
Medical Devices

Education

Lists including Mark

AH
AL
AS
AD

Based in Seattle

494 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Icosavax

Series A

Total Funding: $150M

Platelet BioGenesis

Series A

Total Funding: $26M

Talaris Therapeutics

Series A

Total Funding: $100M

WindMIL Therapeutics

Series B

Total Funding: $33M

Twine Health

Series A

Total Funding: $2M

ZappRx

Series B

Total Funding: $40M

Work Experience

QV
Qiming Venture Partners USA

2017

  • Co Founder and Partner

    2017

    Healthcare-focused US venture fund linked to Qiming's strong China network

U
UCB

2008 - 2016

  • EVP and Chief Operating Officer

    2008 - 2016

PDL BioPharma

2002 - 2007

  • CEO

    2002 - 2007

Signature BioScience

2001 - 2002

  • Chief Executive Officer

    2001 - 2002

CC
Corixa Corporation

1994 - 2000

  • Co-founder and COO

    1994 - 2000

Boehringer Mannheim Therapeutics

1992 - 1994

  • COO

    1992 - 1994